Your session is about to expire
← Back to Search
NCX 470 for Glaucoma (Denali Trial)
Denali Trial Summary
This trial will study whether NCX 470 Ophthalmic Solution is safe and effective in lowering eye pressure in people with ocular hypertension or glaucoma.
Denali Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDenali Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Denali Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your vision with glasses or contacts must be good in each eye.I have had complex or specific glaucoma surgery in either eye.I haven't had eye surgery or severe eye trauma in the last 6 months.I have a disease that is not currently under control.I have a serious eye condition.My eye's front chamber is narrow or my cornea is too thin.I have been diagnosed with glaucoma or high eye pressure in both eyes.My eye pressure was measured 3 times a day during 2 visits after stopping any eye pressure medication.
- Group 1: NCX 470 0.1%
- Group 2: Latanoprost 0.005%
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Will people who are over the age of 40 be able to participate in this clinical trial?
"This study's inclusion criteria allow for participants that are aged 18 to 84."
What is the most severe reaction that has been linked with NCX 470 0.1%?
"There is some evidence to support NCX 470 0.1% efficacy and multiple rounds of data that suggest the safety of the drug, so it received a score of 3."
Are there any areas in this research project that still need participants?
"That is correct. As of 9/21/2022, the most recent update, this clinical trial is actively searching for 670 participants from a single location."
What are the benefits of NCX 470 0.1% ?
"NCX 470 0.1% is a medication used to treat open angle glaucoma, increased intra ocular pressure, and chronic angle-closure glaucoma. This medication is also taken as a preventative measure for patients that have undergone peripheral iridotomy or laser iridoplasty."
Share this study with friends
Copy Link
Messenger